Literature DB >> 25616572

Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program.

Vincent Barlogis1, Pascal Auquier2, Yves Bertrand3, Pascal Chastagner4, Dominique Plantaz5, Maryline Poiree6, Justyna Kanold7, Julie Berbis2, Claire Oudin8, Camille Vercasson2, Maya Allouche8, Marie-Dominique Tabone9, Sandrine Thouvenin-Doulet10, Laure Saumet11, Hervé Chambost8, André Baruchel12, Guy Leverger9, Gérard Michel13.   

Abstract

Entities:  

Keywords:  Leucémie Enfant & Adolescent program; late cardiomyopathy; pediatric acute myeloid leukemia

Mesh：

Year:  2015        PMID： 25616572      PMCID： PMC4420228          DOI： 10.3324/haematol.2014.116574

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

Authors:  K Nysom; K Holm; S R Lipsitz; S M Mone; S D Colan; E J Orav; S E Sallan; J H Olsen; H Hertz; J R Jacobsen; S E Lipshultz
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

2.  Cohort Profile: the French childhood cancer survivor study for leukaemia (LEA Cohort).

Authors:  Julie Berbis; Gérard Michel; André Baruchel; Yves Bertrand; Pascal Chastagner; François Demeocq; Justyna Kanold; Guy Leverger; Dominique Plantaz; Marilyne Poirée; Jean-Louis Stephan; Pascal Auquier; Audrey Contet; Jean-Hugues Dalle; Stéphane Ducassou; Virginie Gandemer; Patrick Lutz; Nicolas Sirvent; Marie-Dominique Tabone; Sandrine Thouvenin-Doulet
Journal:  Int J Epidemiol       Date:  2014-03-17       Impact factor: 7.196

3.  Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.

Authors:  Ursula Creutzig; Sylke Diekamp; Martin Zimmermann; Dirk Reinhardt
Journal:  Pediatr Blood Cancer       Date:  2007-06-15       Impact factor: 3.167

4.  Late effects of treatment in survivors of childhood acute myeloid leukemia.

Authors:  W Leung; M M Hudson; D K Strickland; S Phipps; D K Srivastava; R C Ribeiro; J E Rubnitz; J T Sandlund; L E Kun; L C Bowman; B I Razzouk; P Mathew; P Shearer; W E Evans; C H Pui
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

5.  Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

Authors:  K Sorensen; G Levitt; C Bull; J Chessells; I Sullivan
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

6.  Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.

Authors:  G Michel; E Gluckman; H Esperou-Bourdeau; J Reiffers; J L Pico; P Bordigoni; I Thuret; D Blaise; F Bernaudin; J P Jouet
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

Review 7.  Pediatric acute myeloid leukemia: towards high-quality cure of all patients.

Authors:  Gertjan J L Kaspers; Christian M Zwaan
Journal:  Haematologica       Date:  2007-11       Impact factor: 9.941

8.  Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.

Authors:  Marie-Cécile Le Deley; Thierry Leblanc; Akthar Shamsaldin; Marie-Anne Raquin; Brigitte Lacour; Danièle Sommelet; Agnès Chompret; Jean-Michel Cayuela; Chantal Bayle; Alain Bernheim; Florent de Vathaire; Gilles Vassal; Catherine Hill
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

Review 9.  Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group.

Authors:  Sadhna M Shankar; Neyssa Marina; Melissa M Hudson; David C Hodgson; M Jacob Adams; Wendy Landier; Smita Bhatia; Kathleen Meeske; Ming Hui Chen; Karen E Kinahan; Julia Steinberger; David Rosenthal
Journal:  Pediatrics       Date:  2008-01-10       Impact factor: 7.124

10.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Authors:  S E Lipshultz; S D Colan; R D Gelber; A R Perez-Atayde; S E Sallan; S P Sanders
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245
View more
  6 in total

1.  Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes.

Authors:  Nathan J Schloemer; Molly Brickler; Raymond Hoffmann; Amy Pan; Pippa Simpson; Vanessa McFadden; Joseph Block; Richard L Tower; Michael J Burke
Journal:  J Pediatr Hematol Oncol       Date:  2017-07       Impact factor: 1.289

2.  Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.

Authors:  Jeffrey E Rubnitz; Norman J Lacayo; Hiroto Inaba; Kenneth Heym; Raul C Ribeiro; Jeffrey Taub; Jennifer McNeer; Barbara Degar; Deborah Schiff; Allen Eng-Juh Yeoh; Elaine Coustan-Smith; Lei Wang; Brandon Triplett; Susana C Raimondi; Jeffery Klco; John Choi; Stanley Pounds; Ching-Hon Pui
Journal:  J Clin Oncol       Date:  2019-06-27       Impact factor: 44.544

3.  Minimizing cardiac toxicity in children with acute myeloid leukemia.

Authors:  Hari K Narayan; Kelly D Getz; Kasey J Leger
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML.

Authors:  Kavitha Ramaswamy; Peter G Steinherz; Anurag K Agrawal; Christopher J Forlenza; Audrey Mauguen; Mikhail Roshal; Tanya Trippett; Nancy A Kernan; Maria Luisa Sulis; Neerav Shukla
Journal:  Blood Adv       Date:  2022-04-26

5.  Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study.

Authors:  Neel S Bhatt; Malek J Baassiri; Wei Liu; Nickhill Bhakta; Wassim Chemaitilly; Matthew J Ehrhardt; Hiroto Inaba; Kevin Krull; Kirsten K Ness; Jeffrey E Rubnitz; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney
Journal:  Leukemia       Date:  2021-01-25       Impact factor: 11.528

6.  Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO-AML Study.

Authors:  Mari Wilhelmsson; Heidi Glosli; Marianne Ifversen; Jonas Abrahamsson; Jacek Winiarski; Kirsi Jahnukainen; Henrik Hasle
Journal:  Bone Marrow Transplant       Date:  2018-09-21       Impact factor: 5.483
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.